204 related articles for article (PubMed ID: 30681320)
1. Rethinking Glioblastoma Therapy: MDA-9/Syntenin Targeted Small Molecule.
Das SK; Sarkar D; Cavenee WK; Emdad L; Fisher PB
ACS Chem Neurosci; 2019 Mar; 10(3):1121-1123. PubMed ID: 30681320
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of radiation-induced glioblastoma invasion by genetic and pharmacological targeting of MDA-9/Syntenin.
Kegelman TP; Wu B; Das SK; Talukdar S; Beckta JM; Hu B; Emdad L; Valerie K; Sarkar D; Furnari FB; Cavenee WK; Wei J; Purves A; De SK; Pellecchia M; Fisher PB
Proc Natl Acad Sci U S A; 2017 Jan; 114(2):370-375. PubMed ID: 28011764
[TBL] [Abstract][Full Text] [Related]
3. MDA-9/syntenin is a key regulator of glioma pathogenesis.
Kegelman TP; Das SK; Hu B; Bacolod MD; Fuller CE; Menezes ME; Emdad L; Dasgupta S; Baldwin AS; Bruce JN; Dent P; Pellecchia M; Sarkar D; Fisher PB
Neuro Oncol; 2014 Jan; 16(1):50-61. PubMed ID: 24305713
[TBL] [Abstract][Full Text] [Related]
4. Clipping the Wings of Glioblastoma: Modulation of WNT as a Novel Therapeutic Strategy.
Suwala AK; Hanaford A; Kahlert UD; Maciaczyk J
J Neuropathol Exp Neurol; 2016 May; 75(5):388-96. PubMed ID: 26979081
[TBL] [Abstract][Full Text] [Related]
5. Glioblastoma chemotherapeutic agents used in the clinical setting and in clinical trials: Nanomedicine approaches to improve their efficacy.
Aparicio-Blanco J; Sanz-Arriazu L; Lorenzoni R; Blanco-Prieto MJ
Int J Pharm; 2020 May; 581():119283. PubMed ID: 32240807
[TBL] [Abstract][Full Text] [Related]
6. Use of nanoparticles for drug delivery in glioblastoma multiforme.
Jain KK
Expert Rev Neurother; 2007 Apr; 7(4):363-72. PubMed ID: 17425491
[TBL] [Abstract][Full Text] [Related]
7. Recent developments in drug delivery strategies for targeting DNA damage response in glioblastoma.
Morás AM; Henn JG; Steffens Reinhardt L; Lenz G; Moura DJ
Life Sci; 2021 Dec; 287():120128. PubMed ID: 34774874
[TBL] [Abstract][Full Text] [Related]
8. A High-Affinity Peptide Ligand Targeting Syntenin Inhibits Glioblastoma.
Haugaard-Kedström LM; Clemmensen LS; Sereikaite V; Jin Z; Fernandes EFA; Wind B; Abalde-Gil F; Daberger J; Vistrup-Parry M; Aguilar-Morante D; Leblanc R; Egea-Jimenez AL; Albrigtsen M; Jensen KE; Jensen TMT; Ivarsson Y; Vincentelli R; Hamerlik P; Andersen JH; Zimmermann P; Lee W; Strømgaard K
J Med Chem; 2021 Feb; 64(3):1423-1434. PubMed ID: 33502198
[TBL] [Abstract][Full Text] [Related]
9. Drug cocktails for effective treatment of glioblastoma multiforme.
Debinski W
Expert Rev Neurother; 2008 Apr; 8(4):515-7. PubMed ID: 18416653
[No Abstract] [Full Text] [Related]
10. Delivery systems and molecular targets of mechanism-based therapies for GBM.
Phuphanich S; Brat DJ; Olson JJ
Expert Rev Neurother; 2004 Jul; 4(4):649-63. PubMed ID: 15853584
[TBL] [Abstract][Full Text] [Related]
11. Novel delivery strategies for glioblastoma.
Zhou J; Atsina KB; Himes BT; Strohbehn GW; Saltzman WM
Cancer J; 2012; 18(1):89-99. PubMed ID: 22290262
[TBL] [Abstract][Full Text] [Related]
12. Current Challenges and Opportunities in Treating Glioblastoma.
Shergalis A; Bankhead A; Luesakul U; Muangsin N; Neamati N
Pharmacol Rev; 2018 Jul; 70(3):412-445. PubMed ID: 29669750
[TBL] [Abstract][Full Text] [Related]
13. Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance.
Taylor TE; Furnari FB; Cavenee WK
Curr Cancer Drug Targets; 2012 Mar; 12(3):197-209. PubMed ID: 22268382
[TBL] [Abstract][Full Text] [Related]
14. A comprehensive review in improving delivery of small-molecule chemotherapeutic agents overcoming the blood-brain/brain tumor barriers for glioblastoma treatment.
Wang D; Wang C; Wang L; Chen Y
Drug Deliv; 2019 Dec; 26(1):551-565. PubMed ID: 31928355
[TBL] [Abstract][Full Text] [Related]
15. Activation of KATP channels increases anticancer drug delivery to brain tumors and survival.
Ningaraj NS; Sankpal UT; Khaitan D; Meister EA; Vats T
Eur J Pharmacol; 2009 Jan; 602(2-3):188-93. PubMed ID: 19027730
[TBL] [Abstract][Full Text] [Related]
16. Targeting βIII-tubulin in glioblastoma multiforme: from cell biology and histopathology to cancer therapeutics.
Katsetos CD; Draber P; Kavallaris M
Anticancer Agents Med Chem; 2011 Oct; 11(8):719-28. PubMed ID: 21707498
[TBL] [Abstract][Full Text] [Related]
17. Editorial: targeted therapy for glioblastoma multiforme.
Halatsch ME
Anticancer Agents Med Chem; 2011 Oct; 11(8):692. PubMed ID: 21864239
[No Abstract] [Full Text] [Related]
18. Novel function of MDA-9/Syntenin (SDCBP) as a regulator of survival and stemness in glioma stem cells.
Talukdar S; Das SK; Pradhan AK; Emdad L; Shen XN; Windle JJ; Sarkar D; Fisher PB
Oncotarget; 2016 Aug; 7(34):54102-54119. PubMed ID: 27472461
[TBL] [Abstract][Full Text] [Related]
19. Drug delivery approaches for the treatment of glioblastoma multiforme.
Fakhoury M
Artif Cells Nanomed Biotechnol; 2016 Sep; 44(6):1365-73. PubMed ID: 26046399
[TBL] [Abstract][Full Text] [Related]
20. Suppression of Prostate Cancer Pathogenesis Using an MDA-9/Syntenin (SDCBP) PDZ1 Small-Molecule Inhibitor.
Das SK; Kegelman TP; Pradhan AK; Shen XN; Bhoopathi P; Talukdar S; Maji S; Sarkar D; Emdad L; Fisher PB
Mol Cancer Ther; 2019 Nov; 18(11):1997-2007. PubMed ID: 31345950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
